



BioSyent Inc.
Q1 2025 Results
MAY 15, 2025

PRESENTED BY: RENÉ GOEHRUM
PRESIDENT AND CEO



DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSynt Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSynt Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

All values in CAD unless otherwise indicated.





RepaGyn®

Cathejell®

inofolic® MD



^cTibella®

Tibelia Global




Proktis-M®

Combogesic® MD



Sales, EBITDA and NIAT

Quarter ended March 31st (Q1)




Q1 2025 Sales Summary (\$)

	Q1 2025 Sales (\$)	Q1 '25 vs. Q4 '24 (%)
Canadian Pharma (\$)	\$9,160k	+21%
Cathejell®		+15%
Combogesic®		(30%)
FeraMAX® Pd		+18%
Gelclair®		(21%)
Inofolic®		+401%
RepaGyn®		+9%
Tibella® (Canada)		+53%
International Pharma (\$)	\$1,535k	n/a
Legacy (\$)	\$284k	+52%
Total Company (\$)	\$10,979k	+42%

Fully Diluted Earnings per Share (TTM)

59 Consecutive
Profitable Quarters
to Q1 2025



2025 YTD Highlights



Tibelia Global

- Jan/Feb 2025: First Tibelia® Global shipments made by BioSyent: ~\$0.8 million in incremental revenue
 - Orders booked for shipping Q2, Q3, Q4
- Mar 2025: Paid Q1 2025 dividend of \$0.05/share (+11% increase vs. 2024) 
- May 2025: Q2 2025 Dividend of \$0.05/share declared
- Apr 2025: FeraMAX® named #1 recommended iron supplement in Canada for **tenth** consecutive year 
- YTD 2025: 19,500 shares repurchased and cancelled under NCIB 

Trade and Tariffs

Uncertainty:

- USA-Canada Tariffs / Counter-Tariffs
- Impact on Global Trade and Economies
- Impact on Supply Chains
- Impact on Canadian Consumers



FeraMAX®



- Most recommended iron supplement in Canada - pharmacists and physicians - **10** consecutive years⁽¹⁾
- Continued innovation and expansion of FeraMAX® product line for iron health

(1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recommendations

FeraMAX[®] LifeCycle Strategy

- Expanding leadership of FeraMAX[®] brand in Canada:

“Iron health for life”

- FeraMAX[®] Pd platform introduced in October 2020
 - Patented delivery system based on Polydextrose Iron Complex (PDIC)



- FeraMAX[®] Pd Therapeutic 150 launched Nov 2020
- FeraMAX[®] Pd Powder 15 launched Oct 2021
- FeraMAX[®] Pd Maintenance 45 launched Mar 2023
- Development of additional FeraMAX[®] Pd Products

Innovations, Product Launches and Acquisitions



Tibella®

Jul 2020



FeraMAX® Pd

Oct 2020



FeraMAX® Pd Therapeutic 150

Nov 2020



Combogesic®

Dec 2020



FeraMAX® Pd Powder 15

Oct 2021



FeraMAX® Pd Maintenance 45

Mar 2023



Inofolic®

Aug 2023



Gelclair®

Nov 2023



Tibelia® Global

Sep 2024



New endocrinology asset

TBD




FeraMAX® Pd products in development

TBD




15 Years of Profitable Growth (and Counting!)



f/d shares: 14,336,194  11,579,121

Cash Balance & Return on Equity (“RoE”)

Trailing Twelve Months ended March 31st




- Zero Debt
- TTM Cash from Operations of **\$7.0M**
- TTM NCIB share buybacks: **\$4.1 M**
- TTM Dividends of **\$2.1M**
- Mar 31/25 Working Capital of **\$22.8M**
- Execution of strategy drives TTM RoE of **22%**



Capital Allocation linked to Strategy

First use of capital is to generate revenue/profit growth & portfolio diversification.



- 7 new product launches in Canada since July 2020
- Tibelia® / Tibella® (tibolone) Global Acquisition in Sept 2024

Stock Information

As at May 13, 2025

Exchange & Trading Symbol	TSXV: RX
May 13, 2025 Closing Stock Price (CAD) (TSXV):	\$10.80
52 Week Hi/Low (TSXV):	\$12.13 / \$8.24
Issued Common Shares:	11,471,121
Treasury – RSU Shares in Trust	<u>(216,483)</u>
Outstanding Common Shares:	11,254,638
Options Outstanding	109,730
RSUs Outstanding	<u>214,753</u>
Fully Diluted Common Shares:	11,579,121
P/E Ratio :	15.99
EV/EBITDA :	9.69



- ✓ PROFITABLE.
- ✓ WELL CAPITALIZED.
- ✓ GROWTH ASSETS.
- ✓ FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN.

